Data from the study with the lead ADC candidate, HDP-101, show elimination of tumor cells in one patient Clinical data from IMS will be presented in R&D webinar on 15 October at 17:00 CEST / 11:00 EDT Ladenburg, Germany, 1 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today […]
– Late-breaking abstract on extended follow-up data from the MATCH Phase 2 trial accepted for poster presentation – Poster presentation on new data highlighting the Company’s discovery platform to differentiate, engineer and cryopreserve macrophages for therapeutic use Edinburgh and London, UK, 29 May 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering […]
Data demonstrate that uPARAP is highly expressed in tumor samples obtained from glioblastoma multiforme patients uPARAP targeting ADC shows cytotoxicity in glioblastoma multiforme cancer cells in vitro and exhibits potent in vivo anti-tumor activity in a glioblastoma multiforme PDX model Data provides evidence that uPARAP targeting ADCs are a potential novel treatment option for glioblastoma multiforme […]
Late breaking presentation on STORM’s METTL1 inhibitors, for the treatment of cancer, on 8 April 2024 26 March 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced that Alexandra Sapetschnig, Group Leader at STORM, […]
Market opportunity estimated to be greater than US$1 billion Key highlights – Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model – Data strengthens and facilitates the expansion of patent applications for POLB 001 in cancer immunotherapy-induced CRS – Independent Advisory Board supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced […]
